Pathogen News and Research

RSS

Immune response to SARS-CoV-2 may be limited by a set of genes

Neutralizing antibodies develop within two weeks of a SARS-CoV-2 infection, but their durability and intensity can vary by individual, prompting concerns about the prospects of long-lasting immunity and efficacy of COVID-19 vaccines.

18 Feb 2021

Endothelial SARS-CoV-2 infection induces proinflammatory responses without supporting viral amplification, finds study

A team of scientists from Australia and Brazil recently investigated the involvement of endothelial cells in the pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

18 Feb 2021

Advancements in DNA vaccines against COVID-19

The rapid spread of the pathogen and the increasing number of cases highlight the need for an effective and safe vaccine. As vaccination efforts roll out in many countries, new types of vaccines, like deoxyribonucleic acid (DNA) vaccines, are under research..

17 Feb 2021

Nasal antiviral blocks SARS-CoV-2 transmission in ferrets

A nasal antiviral created by researchers at Columbia University Vagelos College of Physicians and Surgeons blocked transmission of SARS-CoV-2 in ferrets, suggesting the nasal spray also may prevent infection in people exposed to the new coronavirus, including recent variants.

17 Feb 2021

SARS-CoV-2 nucleoprotein increases infectivity of spike-based pseudoviruses

In a recent study conducted at the Indian Institute of Science Education and Research, India, a team of scientists screened specific genes of SARS-CoV-2 to identify factors that may contribute to viral infectivity.

17 Feb 2021

Probiotics may be beneficial in COVID-19 treatment

A new study explores the role of common probiotics in managing the disease, which could prove to be of great value, given the emergence of new variants and the broad spectrum of clinical disease in COVID-19.

17 Feb 2021

Antibody testing is key to understand immune response to SARS-CoV-2

While PCR testing has been used widely for COVID-19 diagnosis, it only provides information on who is currently infected. Antibody testing can tell who has been previously exposed to SARS-CoV-2, the virus that causes COVID-19, a metric that is essential for tracking spread across a population.

17 Feb 2021

Pan-coronavirus vaccine needed to deal SARS-CoV-2 variants

In an article, published on the JAMA Network and written by health experts, including Dr. Anthony Fauci, American physician-scientist and immunologist serving as the director of the National Institute of Allergy and Infectious Diseases, the authors discuss the need for a pan-coronavirus vaccine, which can protect against most or all variants of SARS-CoV-2.

16 Feb 2021

Virus transmission by dental tools and prevention by antiviral agent

Researchers at the University of Ljubljana have demonstrated how a virus can spread by droplets during ultrasonic scaler (USS) operation and how this spread can be mitigated by merely substituting the irrigant with clinical virucidal agents, namely sodium hypochlorite and EOW (Electrolyzed Oxidizing Water).

16 Feb 2021

Stability and pathogenicity of MERS coronavirus varies across different viral strains

An international team of researchers has conducted a study suggesting that individual variation across different strains of betacoronaviruses can alter their stability and pathogenicity profiles.

16 Feb 2021

Artemisia plant extracts show potential anti-SARS-CoV-2 activity in vitro

A team of scientists from Germany and the USA recently explored the effectiveness of traditional plant medicines in treating SARS-CoV-2 infection.

16 Feb 2021

Clonally expanded plasma cell lineages in SARS-CoV-2 produce specific neutralizing antibodies

A new preprint research paper posted to the bioRxiv server provides a greater understanding of the aspect of humoral immunity against the virus – the plasma cells that pour out a flood of specific antibodies targeting various epitopes on the pathogen.

16 Feb 2021

CDC says vaccinated individuals can skip COVID quarantines

The coronavirus disease (COVID-19) pandemic's global case toll has surpassed 109 million globally. Of these infections, 2.4 million people have already succumbed to the disease. As the pandemic continues to spread, many countries have rolled out vaccinations.

15 Feb 2021

Nanoparticle COVID-19 vaccine stimulates robust and long lasting immunity in primates

In the study, published on the preprint server bioRxiv, the team evaluated the ability of AS03, CpG 1018 formulated in Alum, the TLR-7 agonist adsorbed to Alum (AS37), the squalene-in-water emulsion (O/W), and Alum to boost protective immunity against SARS-CoV-2.

15 Feb 2021

Pitt scientists develop fast, efficient technique for discovering tiny antibody fragments

By capitalizing on a convergence of chemical, biological and artificial intelligence advances, University of Pittsburgh School of Medicine scientists have developed an unusually fast and efficient method for discovering tiny antibody fragments with big potential for development into therapeutics against deadly diseases.

15 Feb 2021

SARS-CoV-2 South Africa and Brazil variants show resistance to therapeutic antibodies

Scientists from Germany have determined the efficacy of currently used therapeutics in treating newer variants of SARS-CoV-2, including the UK, South Africa, and Brazil variants. Their findings reveal that both B.1.351 and B.1.1.248 variants are able to escape humoral immune responses induced by therapeutic antibodies, vaccinations, or natural SARS-CoV-2 infection.

15 Feb 2021

RIG-1-like receptors may play dominant role in suppressing SARS-CoV-2 infection

A new study by researchers at the University of Connecticut Health Center, USA, reports the crucial nature of the pathogen pattern recognition receptor (PRRs), especially the two RLRs, retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated protein 5 (MDA5), in triggering host cell immune responses within the cell. The RLRs are viral RNA sensors.

15 Feb 2021